|
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
|
Jul 2015
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Oct 2015
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
|
Mar 2017
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
The Challenging World of Cytopenias: Distinguishing Myelodysplastic Syndromes From Other Disorders of Marrow Failure
|
Jun 2014
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
|
Aug 2016
|
Oncotarget
|
myelodysplastic syndromes (MDS)
|
|
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.
|
Jun 2017
|
Oncotarget
|
myelodysplastic syndromes (MDS)
|
|
Dysregulated miR34a/diacylglycerol kinase ζ interaction enhances T-cell activation in acquired aplastic anemia
|
Dec 2016
|
Oncotarget
|
aplastic anemia
|
|
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
|
Feb 2017
|
Oncotarget
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
|
Oct 2015
|
PDQ Cancer Information Summaries [Internet]
|
myelodysplastic syndromes (MDS)
|
|
Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia
|
Jul 2012
|
Pediatr Blood Cancer
|
aplastic anemia
|
